Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
CAS: 1147201-50-0
Ref. 3D-XVB20150
| 1g | A consultar | ||
| 5g | A consultar |
Información del producto
Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate (SNX-111) is a novel, orally active, nonselective inhibitor of the enzyme diacylglycerol acyltransferase 2 (DGAT2). SNX-111 is in development for the treatment of lipid metabolism disorders and as an adjunct to diet and exercise. In a study of patients with hyperlipidaemia and type 2 diabetes mellitus, SNX-111 was found to reduce serum triglycerides and cholesterol levels. SNX-111 also reduced blood sugar levels in diabetic patients with elevated blood sugar levels.
SNX-111 has been shown to be well tolerated in short term clinical trials for up to 12 weeks. The most common side effects were headache, diarrhoea, nausea, vomiting and abdominal pain.
Propiedades químicas
Consulta técnica sobre: 3D-XVB20150 Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
